clinical trial · NCT07100080
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb·phase3·recruiting·n = 596
Non-Small Cell Lung CancerIza-brenCarboplatinCisplatinPemetrexed
brief summary
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
started
Nov 5, 2025
primary completion
Sep 15, 2028
completion
May 15, 2031
last updated
Apr 16, 2026
official title
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol